MAPT and Alzheimer disease: The plasma biomarker study, which showed elevated plasma Aβ1‐42, Aβ1‐42/Aβ1‐40 ratio, and total tau levels, was consistent with our previous findings in patients with AD (Chiu et al., 2012, 2013).